DETERMINANTS OF RESPONSE TO T‐CELL STIMULATION BY CD27 ANTIBODY THERAPY IN LYMPHOMA: THE RIVA TRIAL

Kim Linton

Research output: Contribution to journal › Meeting Abstract › peer-review

12 Downloads (Pure)

Original language	English
Journal	Hematological oncology
DOIs	https://doi.org/10.1002/hon.3164_194
Publication status	Published - 9 Jun 2023
Event	International Conference on Malignant Lymphoma - Lugano, Switzerland Duration: 13 Jun 2023 → 17 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
Lim, S. H., Linton, K. M., Collins, G. P., Dhondt, J., Caddy, J., Rossiter, L., Vadher, K., Fines, K., Rogers, L. E., Fernando, D., Stanton, L., Davies, A. J., Johnson, P. W. M. & Griffiths, G., 2018, In: Trials. 19, 1, 1 p.
Research output: Contribution to journal › Article › peer-review

Open Access

@article{d986b8be9b894aad9df3653600d5f67e,

title = "DETERMINANTS OF RESPONSE TO T‐CELL STIMULATION BY CD27 ANTIBODY THERAPY IN LYMPHOMA: THE RIVA TRIAL",

author = "Kim Linton",

year = "2023",

month = jun,

day = "9",

doi = "10.1002/hon.3164_194",

language = "English",

journal = "Hematological oncology",

issn = "0278-0232",

publisher = "John Wiley & Sons Ltd",

note = "International Conference on Malignant Lymphoma, 17-ICML ; Conference date: 13-06-2023 Through 17-06-2023",

}

TY - JOUR

T1 - DETERMINANTS OF RESPONSE TO T‐CELL STIMULATION BY CD27 ANTIBODY THERAPY IN LYMPHOMA: THE RIVA TRIAL

AU - Linton, Kim

PY - 2023/6/9

Y1 - 2023/6/9

U2 - 10.1002/hon.3164_194

DO - 10.1002/hon.3164_194

M3 - Meeting Abstract

SN - 0278-0232

JO - Hematological oncology

JF - Hematological oncology

T2 - International Conference on Malignant Lymphoma

Y2 - 13 June 2023 through 17 June 2023

ER -